FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2915059612> ?p ?o ?g. }

• W2915059612 abstract "Currently available prophylactic migraine treatment options are limited and are associated with many, often intolerable, side-effects. Various lines of research suggest that abnormalities in energy metabolism are likely to be part of migraine pathophysiology. Previously, a ketogenic diet (KD) has been reported to lead to a drastic reduction in migraine frequency. An alternative method to a strict KD is inducing a mild nutritional ketosis (0.4–2 mmol/l) with exogenous ketogenic substances. The aim of this randomised, placebo-controlled, double-blind, crossover, single-centre trial is to demonstrate safety and superiority of beta-hydroxybutyrate (βHB) in mineral salt form over placebo in migraine prevention. Forty-five episodic migraineurs (5–14 migraine days/months), with or without aura, aged between 18 and 65 years, will be recruited at headache clinics in Switzerland, Germany and Austria and via Internet announcements. After a 4-week baseline period, patients will be randomly allocated to one of the two trial arms and receive either the βHB mineral salt or placebo for 12 weeks. This will be followed by a 4-week wash-out period, a subsequent second baseline period and, finally, another 12-week intervention with the alternative treatment. Co-medication with triptans (10 days per months) or analgesics (14 days per months) is permitted. The primary outcome is the mean change from baseline in the number of migraine days (meeting International Classification of Headache Disorders version 3 criteria) during the last 4 weeks of intervention compared to placebo. Secondary endpoints include mean changes in headache days of any severity, acute migraine medication use, migraine intensity and migraine and headache-related disability. Exploratory outcomes are (in addition to routine laboratory analysis) genetic profiling and expression analysis, oxidative and nitrosative stress, as well as serum cytokine analysis, and blood βHB and glucose analysis (pharmacokinetics). A crossover design was chosen as it greatly improves statistical power and participation rates, without increasing costs. To our knowledge this is the first RCT using βHB salts worldwide. If proven effective and safe, βHB might not only offer a new prophylactic treatment option for migraine patients, but might additionally pave the way for clinical trials assessing its use in related diseases. ClinicalTrials.gov, NCT03132233 . Registered on 27 April 2017." @default.
• W2915059612 created "2019-02-21" @default.
• W2915059612 creator A5009975789 @default.
• W2915059612 creator A5014641453 @default.
• W2915059612 creator A5030818202 @default.
• W2915059612 creator A5049110219 @default.
• W2915059612 creator A5057598527 @default.
• W2915059612 creator A5079279108 @default.
• W2915059612 creator A5080502901 @default.
• W2915059612 creator A5086320160 @default.
• W2915059612 date "2019-01-17" @default.
• W2915059612 modified "2023-10-17" @default.
• W2915059612 title "Efficacy and safety of exogenous ketone bodies for preventive treatment of migraine: A study protocol for a single-centred, randomised, placebo-controlled, double-blind crossover trial" @default.
• W2915059612 cites W1592314383 @default.
• W2915059612 cites W1603155066 @default.
• W2915059612 cites W1875927246 @default.
• W2915059612 cites W1964626003 @default.
• W2915059612 cites W1969507790 @default.
• W2915059612 cites W1973124376 @default.
• W2915059612 cites W1973157975 @default.
• W2915059612 cites W1975894948 @default.
• W2915059612 cites W1978425109 @default.
• W2915059612 cites W1980350110 @default.
• W2915059612 cites W1995699180 @default.
• W2915059612 cites W1998775237 @default.
• W2915059612 cites W2001216459 @default.
• W2915059612 cites W2001570194 @default.
• W2915059612 cites W2010511534 @default.
• W2915059612 cites W2012825395 @default.
• W2915059612 cites W2013033676 @default.
• W2915059612 cites W2014208168 @default.
• W2915059612 cites W2020994182 @default.
• W2915059612 cites W2023983971 @default.
• W2915059612 cites W2025549939 @default.
• W2915059612 cites W2032998415 @default.
• W2915059612 cites W2033482028 @default.
• W2915059612 cites W2037020759 @default.
• W2915059612 cites W2040919569 @default.
• W2915059612 cites W2045600498 @default.
• W2915059612 cites W2062447656 @default.
• W2915059612 cites W2066118234 @default.
• W2915059612 cites W2069479983 @default.
• W2915059612 cites W2069717614 @default.
• W2915059612 cites W2081238840 @default.
• W2915059612 cites W2083316062 @default.
• W2915059612 cites W2085522994 @default.
• W2915059612 cites W2090648636 @default.
• W2915059612 cites W2096399156 @default.
• W2915059612 cites W2096876097 @default.
• W2915059612 cites W2096883662 @default.
• W2915059612 cites W2101304481 @default.
• W2915059612 cites W2104531364 @default.
• W2915059612 cites W2106884116 @default.
• W2915059612 cites W2110718047 @default.
• W2915059612 cites W2114445980 @default.
• W2915059612 cites W2117309102 @default.
• W2915059612 cites W2122311626 @default.
• W2915059612 cites W2123280655 @default.
• W2915059612 cites W2123514356 @default.
• W2915059612 cites W2128676798 @default.
• W2915059612 cites W2130833936 @default.
• W2915059612 cites W2134072971 @default.
• W2915059612 cites W2134578184 @default.
• W2915059612 cites W2135017807 @default.
• W2915059612 cites W2141342357 @default.
• W2915059612 cites W2144159191 @default.
• W2915059612 cites W2146890278 @default.
• W2915059612 cites W2152290674 @default.
• W2915059612 cites W2152994958 @default.
• W2915059612 cites W2157733244 @default.
• W2915059612 cites W2159846350 @default.
• W2915059612 cites W2166901713 @default.
• W2915059612 cites W2171127680 @default.
• W2915059612 cites W2172136900 @default.
• W2915059612 cites W2242867596 @default.
• W2915059612 cites W2268191745 @default.
• W2915059612 cites W2397133898 @default.
• W2915059612 cites W2408910873 @default.
• W2915059612 cites W2761703425 @default.
• W2915059612 cites W2793750862 @default.
• W2915059612 doi "https://doi.org/10.1186/s13063-018-3120-7" @default.
• W2915059612 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6337840" @default.
• W2915059612 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30654835" @default.
• W2915059612 hasPublicationYear "2019" @default.
• W2915059612 type Work @default.
• W2915059612 sameAs 2915059612 @default.
• W2915059612 citedByCount "17" @default.
• W2915059612 countsByYear W29150596122019 @default.
• W2915059612 countsByYear W29150596122020 @default.
• W2915059612 countsByYear W29150596122021 @default.
• W2915059612 countsByYear W29150596122022 @default.
• W2915059612 countsByYear W29150596122023 @default.
• W2915059612 crossrefType "journal-article" @default.
• W2915059612 hasAuthorship W2915059612A5009975789 @default.
• W2915059612 hasAuthorship W2915059612A5014641453 @default.
• W2915059612 hasAuthorship W2915059612A5030818202 @default.
• W2915059612 hasAuthorship W2915059612A5049110219 @default.
• W2915059612 hasAuthorship W2915059612A5057598527 @default.
• W2915059612 hasAuthorship W2915059612A5079279108 @default.
• W2915059612 hasAuthorship W2915059612A5080502901 @default.

• next